期刊
CANCER AND METASTASIS REVIEWS
卷 24, 期 4, 页码 585-598出版社
SPRINGER
DOI: 10.1007/s10555-005-6197-x
关键词
monoclonal antibody; oncology; antibody manufacture; antibody-dependent cell cytotoxicity (ADCC); complement-mediated cytolysis (CMC); clinical trial
类别
The past five years have witnessed the emergence of monoclonal antibodies as important therapeutics for cancer treatment. Lower toxicity for antibodies versus small molecules, the potential for increased efficacy by conjugation to radioisotopes and cellular toxins, or the ability to exploit immune cell functions have led to clinical performances on par or superior to conventional drug therapies. This review outlines the various immunoglobulin design strategies currently available, techniques used to reduce Ig antigenicity and toxicity, and points to consider during the manufacture of antibodies for use in clinical oncology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据